GTG Genetic Technologies

Genetic Technologies CEO to Participate in Investor Webinar and Q&A Session on June 24, 2020

Genetic Technologies CEO to Participate in Investor Webinar and Q&A Session on June 24, 2020

MELBOURNE, Australia, June 23, 2020 (GLOBE NEWSWIRE) -- Molecular diagnostics company Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) (the “Company”) is pleased to announce that its interim-CEO Dr. George Muchnicki will share insight into the Company’s recent developments during an investor webinar, hosted by RedChip Companies, on Wednesday, June 24, 2020 at 4:00 p.m. ET. A live Q&A session with Dr. Muchnicki will follow the presentation.

To register for the free webinar, please visit:

About Genetic Technologies Limited

Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE) is a diversified molecular diagnostics company. GTG offers cancer predictive testing and assessment tools to help physicians proactively manage patient health. The Company’s lead products GeneType for Breast Cancer for non-hereditary breast cancer and GeneType for Colorectal Cancer are clinically validated risk assessment tests and are first in class.

Genetic Technologies has capacity for COVID-19 testing and is developing a pipeline of risk assessment products.

For more information, please visit .

Contact: 

Dave Gentry, CEO

RedChip Companies

Office: 1 800 RED CHIP (733 2447)

Cell: US 407 491 4498

 

EN
23/06/2020

Underlying

GTGGenetic Technologies

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Genetic Technologies

 PRESS RELEASE
Free
GTG Genetic Technol...

Join Genetic Technology’s Exclusive Live Investor Webinar and Q&A Sess...

Join Genetic Technology’s Exclusive Live Investor Webinar and Q&A Session on October 2 MELBOURNE, Australia, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE, “Company”, “GTG”, or “Genetic Technologies”), a global leader in guideline-driven genomics-based tests in health, wellness and serious diseases, is pleased to invite investors to a webinar on October 2, 2024, at 4:15 p.m. ET. The exclusive event, hosted by RedChip Companies, will feature Genetic Technologies’ senior leadership who will share insight into the Company’s portfolio of genomics-based...

September 23, 2024 1 EN
 PRESS RELEASE
Free
GTG Genetic Technol...

Genetic Technologies Invited to Join Prestigious “CancerIQ” Online Pla...

Genetic Technologies Invited to Join Prestigious “CancerIQ” Online Platform - Provides Access to 45 Healthcare Systems and 250 Clinics MELBOURNE, Australia, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to announce the Company has negotiated a partnership agreement with Chicago-based CancerIQ. CancerIQ enables Healthcare Institutions and Clinics to support cancer prevention programs by supporting and simplifying the identification ...

September 11, 2024 1 EN
 PRESS RELEASE
Free
GTG Genetic Technol...

Genetic Technologies Announces Global Launch of geneType™ on Wholly Ow...

Genetic Technologies Announces Global Launch of geneType™ on Wholly Owned EasyDNA platform CHARLOTTE, N.C., Aug. 15, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader in genomics-based tests in health, wellness and serious disease and the parent company of geneType™, is pleased to announce the global launch of the geneType™ Risk Assessment portfolio on our wholly owned EasyDNA platform currently selling in 42 countries, setting the stage for the potential significant expansion of the Company’s current A$7.5m annual revenues....

August 15, 2024 1 EN
 PRESS RELEASE
Free
GTG Genetic Technol...

Join Genetic Technology’s Exclusive Live Investor Webinar and Q&A Sess...

Join Genetic Technology’s Exclusive Live Investor Webinar and Q&A Session on August 15 MELBOURNE, Australia, Aug. 09, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE, “Company”, “GTG”, or “Genetic Technologies”), a global leader in guideline-driven genomics-based tests in health, wellness and serious diseases, is pleased to invite investors to a webinar on August 15, 2024, at 4:15 p.m. ET. The exclusive event, hosted by RedChip Companies, will feature some of Genetic Technologies Senior Executives, who will share insight into the Company’s portfolio of genomic...

August 9, 2024 1 EN
 PRESS RELEASE
Free
GTG Genetic Technol...

Genetic Technologies Strategic Restructure Driving USA Sales Growth

Genetic Technologies Strategic Restructure Driving USA Sales Growth CHARLOTTE, N.C., July 26, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader in genomics-based tests in health, wellness and serious disease and the parent company of geneType™, has conducted an operations review and announces that it intends to transition to a capital light operations model – which is anticipated to result in an immediate material reduction in operating costs. This capital light operations model is intended to focus on sales growth (particul...

July 26, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch